Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.

Considering the total trial population irrespective of MGMT status, a clear trend towards a survival benefit from nimotuzumab was already detectable when tumors had above median levels of phosphorylated ribosomal protein S6.

also in 19,460 other papers

This unplanned subgroup analysis, however, included only 28 patients and failed to reach statistical significance.

also in 6,035 other papers

Within the group of above median value necrotic tumors, nimotuzumab treatment resulted in a slight trend towards improved survival, whereas no trend was detectable in below or median value necrotic tumors (Fig. 3a ).

also in 4,078 other papers